Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336916 | 0.90 | MEN1 (0.42) | LMNAHTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4477132 | 0.89 | LMNA (0.50) | LMNAHTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL2728496 | 0.87 | EGLN1 (0.44) | LMNAHTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4482031 | 0.83 | P2RX7 (0.44) | P2RX7LMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4473406 | 0.83 | ALDH1A1 (0.42) | P2RX7LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL10233986 | 0.83 | EGLN1 (0.43) | P2RX7LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL6031443 | 0.82 | MEN1 (0.37) | LMNAHTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL1335829 | 0.81 | MEN1 (0.37) | P2RX7LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL1337301 | 0.79 | ALDH1A1 (0.38) | P2RX7LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL6032207 | 0.79 | MEN1 (0.34) | P2RX7LMNAHTTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881825-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | VACCA JOSEPH P (US) | 2013-07-11 | — | — | US | disclosed |
| US-8293731-B2 | HIV integrase inhibitors | Merck Sharp + Dohme Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110275621-A1 | HIV INTEGRASE INHIBITORS | SCHERING CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-7968564-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100216834-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-26 | — | — | US | disclosed |
| US-20100216834-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-26 | — | — | US | disclosed |
| US-20100216834-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-26 | — | — | US | disclosed |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-7741315-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-2084160-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| WO-2008048538-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048538-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1881825-A2 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006121831-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216834-A1 | HIV INTEGRASE INHIBITORS | REV1, CDK9, INTS9 | P2RX7 2983/4885LMNA 2777/4885HTT 4845/4885 |
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | REV1, POLR1A, POLR2H | P2RX7 3897/4885LMNA 2654/4885HTT 4776/4885 |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | P2RX7 4051/4885LMNA 2820/4885HTT 4717/4885 |
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | TYMP, SAMHD1, ACIN1 | P2RX7 4649/4885LMNA 2302/4885HTT 1519/4885 |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | P2RX7 4051/4885LMNA 2820/4885HTT 4717/4885 |
| US-20110275621-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | P2RX7 4051/4885LMNA 2820/4885HTT 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.